Last reviewed · How we verify
Influenzinum (H3N2)
At a glance
| Generic name | H3N2 |
|---|---|
| Sponsor | Boiron |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- flu-like symptoms
Common side effects
- Pain (injection-site)
- Headache
- Myalgia
- Redness (injection-site)
- Irritability
- Drowsiness
- Malaise
Key clinical trials
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (PHASE3)
- Influenza Human Challenge Model (PHASE1)
- A/Texas Flu Challenge (PHASE1)
- Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above (PHASE2)
- A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above (PHASE1)
- Establishing a Controlled Human Infection Model for Influenza H3N2 as a Foundation for Pandemic Preparedness (PHASE1)
- Randomized Influenza Vaccine Evaluation of Immune Response (PHASE4)
- Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Influenzinum CI brief — competitive landscape report
- Influenzinum updates RSS · CI watch RSS
- Boiron portfolio CI